What is PT-141?

PT-141, also known as Bremelanotide, is a synthetic peptide used primarily to treat sexual dysfunction in both men and women. It is particularly recognized for its role in treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike other medications that target the vascular system, PT-141 works through the central nervous system to enhance sexual arousal.

Mechanism of Action

PT-141 functions by activating melanocortin receptors, specifically the MC3R and MC4R, in the central nervous system. This activation stimulates pathways that lead to increased sexual desire and arousal by influencing neurotransmitter release related to sexual function.

Clinical Applications

PT-141 is primarily used to treat conditions related to sexual dysfunction. Its most prominent use is in addressing hypoactive sexual desire disorder (HSDD) in premenopausal women, where it has shown efficacy in increasing sexual desire and arousal. It is also being explored for its potential benefits in treating erectile dysfunction in men, although its primary approval and research focus remain on female sexual health.

Safety & Side Effects

PT-141 is generally well-tolerated, but like any medication, it may cause side effects. The most common side effect reported is nausea, which can be mild to moderate in severity. Other side effects may include headache, flushing, and localized reactions at the injection site. It’s important for patients to discuss their full medical history with their healthcare provider to ensure PT-141 is a safe option for them. Regular monitoring and consultation with a healthcare professional are advised to manage any adverse effects effectively.